Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Innovative Pharmaceutical Biotech (0399) Stock Price & Analysis

0 Followers

0399 Stock Chart & Stats

HK$0.07HK$0.00(0.00%)
At close: 4:00 PM GMT+8
HK$0.1HK$0.2HK$0.3Feb 9Feb 23Mar 9Mar 23Apr 8Apr 20May 4
Day’s Range
HKD 0.06 - HKD 0.11
52-Week Range
HKD 0.05 - HKD 0.44
Previous Close
HKD 0.07
Volume
N/A
Average Volume (3M)
0
Market Cap
HKD 231.21M
Enterprise Value
HKD 2.52B
Total Cash (Recent Filing)
HKD 18.07M
Total Debt (Recent Filing)
HKD 1.09B
Price to Earnings (P/E)
―
Beta
1.15
Next Earnings
Nov 27, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Improving Cash Flow Trend

Reported improvement in cash burn and positive free cash flow growth in the latest year suggests the business may be moving toward self-funding or at least reduced external funding needs. If sustained, this improves durability of operations and reduces refinancing pressure over the medium term.

Historic Profitable Episodes

The firm has produced profit in prior years (notably 2022 and 2024), indicating the underlying business can reach positive margins. These episodes show operational levers and demand elasticity that, if management restores revenue stability, could enable durable margin recovery and cash generation.

Lean Operating Footprint

A very small headcount implies a lean cost base and lower fixed overhead, improving flexibility to scale down or pivot with limited restructuring friction. Combined with low beta, this suggests lower equity volatility and potential for steadier operating adjustments across cycles.

Bears Say

Negative Shareholders' Equity

Persistently negative equity is a structural solvency concern that constrains financing options, raises bankruptcy or restructuring risk, and can trigger lender covenants. This materially weakens long-term capital stability and limits capacity to absorb losses or fund growth without dilution.

Large, Persistent Debt Burden

A sizeable and persistent debt load relative to the capital base increases interest and refinancing risk, especially given negative equity and uneven cash flows. Over the medium term, high leverage can force asset sales, costly refinancing, or covenant-driven restructurings that impair strategic options.

Multi-year Revenue Decline And Volatile Profitability

Sustained revenue erosion and a sharp ~53% decline in 2025 undermine scale economics and make margins volatile (gross margins thin at ~9–13%). Structural revenue weakness limits ability to rebuild profitability and makes long-term recovery dependent on meaningful, durable top-line improvements.

Innovative Pharmaceutical Biotech News

0399 FAQ

What was Innovative Pharmaceutical Biotech’s price range in the past 12 months?
Innovative Pharmaceutical Biotech lowest stock price was HK$0.05 and its highest was HK$0.44 in the past 12 months.
What is Innovative Pharmaceutical Biotech’s market cap?
Innovative Pharmaceutical Biotech’s market cap is HK$231.21M.
When is Innovative Pharmaceutical Biotech’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Innovative Pharmaceutical Biotech’s earnings last quarter?
Innovative Pharmaceutical Biotech released its earnings results on Nov 28, 2025. The company reported -HK$0.06 earnings per share for the quarter.
Is Innovative Pharmaceutical Biotech overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Innovative Pharmaceutical Biotech pay dividends?
Innovative Pharmaceutical Biotech does not currently pay dividends.
What is Innovative Pharmaceutical Biotech’s EPS estimate?
Innovative Pharmaceutical Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Innovative Pharmaceutical Biotech have?
Innovative Pharmaceutical Biotech has 3,167,207,000 shares outstanding.
What happened to Innovative Pharmaceutical Biotech’s price movement after its last earnings report?
Innovative Pharmaceutical Biotech reported an EPS of -HK$0.06 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Innovative Pharmaceutical Biotech?
Currently, no hedge funds are holding shares in HK:0399
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology